Pfizer and BioNTech start trials of new Omicron-specific jab
The companies have adapted their original vaccine to target the fast-spreading variant. …
“Staying vigilant against the virus requires us to identify new approaches for people to maintain a high level of protection, and we believe developing and investigating variant-based vaccines, like this one, are essential in our efforts towards this goal,” said Kathrin U. Jansen, senior vice-president and head of vaccine research and development at Pfizer.
About The Author
